Abstract:Immune checkpoint inhibitor (ICI) therapy had achieved significant clinical benefit in multiple malignant solid tumors, such as non-small cell lung cancer, melanoma and urothelial cancer. ICI therapy not only revolutionarily altered the treatment strategy of malignant solid tumors, but also dramatically prolonged overall survival. However, the objective response rate (ORR) of ICI therapy in second line treatment remains 20% or less. How to find patients eligible for ICI therapy by effective biomarkers became hot nowadays. High expression of PD-L1 protein in tumor cells or tumor microenvironment (TME) had been identified to be a logical biomarker for predicting efficacy of ICI therapy and approved by the U.S. Food and Drug Administration to be an indicator of initiating treatment for some solid tumors. Controversially, patients with low PD-L1 protein expression might also show clinical benefit. In this sense, tissue PD-L1 protein expression might not be a precise biomarker. Multimodal detection of PD-L1, such as PD-L1 protein, PD-L1 mRNA, and circulating PD-L1, might provide a comprehensive tumor profile and could find the patients who are more suitable for ICI therapy. Besides, dynamic monitoring of PD-L1 expression could shed light on efficacy assessment and drug resistance. ICI-based combination strategy had demonstrated better outcome than ICI alone. Single biomarker might not be efficient to precisely find advantage patients. Combined biomarkers could better instruct the consideration of therapeutic regimen. In addition, nomogram and artificial intelligence platform could integrate multiparameter information of biomarkers which might shed light on tumor profile and give a hint to treatment decision.

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Biomarkers of response to PD-1/PD-L1 inhibition

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Mechanistic Insight of Predictive Biomarkers for Antitumor PD‑1/PD‑L1 Blockade: A Paradigm Shift Towards Immunome Evaluation (Review)

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer

Advances and prospects of biomarkers for immune checkpoint inhibitors

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1

Predictive Biomarkers for Tumor Immune Checkpoint Blockade

Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma

Predictive Markers for Treating Efficacy of PD-1/PD-L1 Inhibitors in Patients with Lung Cancer: A Review of the 18th World Conference on Lung Cancer

Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor.

Clinical Applications of PD-L1 Bioassays for Cancer Immunotherapy

Companion Diagnostics and Predictive Biomarkers for PD-1/PD-L1 Immune Checkpoint Inhibitors Therapy in Malignant Melanoma